Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3907320 | 0.89 | PRKCA (0.42) | PRKCAPRKCDPOLBTDP1BTN3A1 | |
| SCHEMBL3911478 | 0.84 | CACNA1B (0.44) | PRKCAPRKCDPOLBSYKMAPT | |
| SCHEMBL3913059 | 0.84 | POLB (0.42) | POLBMAPTTDP1 | |
| SCHEMBL23501319 | 0.79 | MAPK1 (0.43) | PRKCAPRKCDMAPTBTN3A1 | |
| SCHEMBL17756121 | 0.78 | POLB (0.45) | POLBSYKMAPTXBP1NPSR1 | |
| SCHEMBL3907689 | 0.78 | SMN1; SMN2 (0.43) | SYKKLK7KLK5 | |
| SCHEMBL15774196 | 0.77 | LMNA (0.47) | SYKMAPTTDP1 | |
| SCHEMBL6976981 | 0.76 | FFAR1 (0.50) | PRKCAPRKCDPOLBLTA4HMAPT | |
| SCHEMBL6976976 | 0.76 | FFAR1 (0.50) | PRKCAPRKCDPOLBLTA4HMAPT | |
| SCHEMBL23501187 | 0.76 | ALDH1A1 (0.60) | PRKCAPRKCDMAPTKLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476759-B2 | e.g. 4-Amino-3-(4'-cyano-1,1'-biphenyl-4-yl)-4-oxobutanoic acid; antiinflammatory , anticarcinogenic, antiasthmatic agent; autoimmune disorder; osteoarthritis, rubella, Alzheimer's, Parkinson's diseases, epilepsy, osteoporosis | GLAXO GROUP LIMITED (GB) | 2009-01-13 | — | — | US | disclosed |
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| EP-1654218-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016868-A2 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235074-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP9, MMP24 | PRKCA 4848/4885PRKCD 4773/4885POLB 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.